Time：Jun 08, 2026
Share：
Millions of women in perimenopause and menopause are looking for solutions that really work. Botanicals with clinical support are gaining attention in women’s wellness.
Shatavari, an ancient herb, is one of the ingredients being studied for midlife health. Standardized extracts like SheVari4™ are now available, making it easier for researchers and brands to study and use shatavari consistently.
This article explains what shatavari is, how it works, the clinical evidence, and its potential benefits for women’s wellness.
What Is Shatavari?
Shatavari (Asparagus racemosus) is a climbing herb native to India and widely used in Ayurvedic medicine for thousands of years. Traditionally known as a “female tonic,” shatavari root benefits have long been recognized for supporting hormonal health, reproductive function, and overall vitality in women across all life stages [1, 3].
The plant’s active compounds are a group of steroidal saponins called shatavarin, with Shatavarin IV recognized as the primary bioactive marker responsible for its hormone-modulating effects [2]. Additional constituents including racemosides, racemosol, and asparagamine A contribute antioxidant activity that further supports the herb’s broad therapeutic profile [4].
Shatavari Hormonal Balance: Three Core Pathways
At a low daily dose, shatavari can support relief across multiple menopause symptoms. Its scientific basis comes down to three core pathways[5–8]:
1. Phytoestrogenic Activity
The root cause of menopause is the natural decline in ovarian estrogen and progesterone. The active constituents in shatavari, especially Shatavarin IV, have been studied for their effects on hormone receptors. Research shows that Shatavarin IV can directly bind to estrogen receptors (ERα, ERβ, ERγ) as well as FSH, LH, and progesterone receptors [5, 6]. This means shatavari can exogenously activate these receptor pathways, mimicking the physiological effects of estrogen and helping to relieve core menopause symptoms including hot flashes, sleep disturbance, and mood fluctuation driven by hormonal withdrawal.
2. Anti-Inflammatory and Antioxidant Protection
The perimenopausal transition is frequently accompanied by elevated systemic low-grade inflammation and oxidative stress. Research indicates shatavari exerts anti-inflammatory, antioxidant, and neuroprotective effects via the TrkB–BDNF signaling axis [8], specifically:
Reducing cerebral and systemic oxidative stress and inflammatory cytokine levels — helping to improve inflammation-associated hot flashes (reduced hypothalamic thermoregulatory sensitivity) and sleep disturbances (decreased neuroinflammation)
Elevating BDNF (brain-derived neurotrophic factor) levels and enhancing neuroplasticity, supporting relief from anxiety and mood-related symptoms
3. HPA Axis Regulation and Adaptogenic Support
As a classic adaptogen, shatavari exerts bidirectional regulatory effects on the hypothalamic–pituitary–adrenal (HPA) axis.Research indicates it can suppress the abnormal elevation of stress hormones (cortisol and norepinephrine) while raising monoamine neurotransmitter levels (serotonin and norepinephrine), providing anti-anxiety and anti-fatigue support [3].
Menopause is a period of both physiological and psychological stress. Shatavari supports HPA axis stability, helping women cope with daily stress more effectively. It may also help improve fatigue and mood fluctuations, areas where conventional hormone-focused supplements often fall short.
Unlike single-pathway botanicals such as ashwagandha, which primarily target cortisol and HPA axis regulation, shatavari acts through multiple pathways simultaneously, including estrogenic, anti-inflammatory, and adaptogenic mechanisms. This broader activity profile makes it a more comprehensive option for supporting women’s hormonal balance.
Shatavari for Menopause: What the Clinical Research Shows
Cepham’s latest prospective, randomized, double-blind, placebo-controlled trial enrolled 60 healthy women aged 40–55 across pre-menopausal, perimenopausal, and postmenopausal stages. Participants received either 100 mg/day of SheVari4 (shatavari root extract, standardized to ≥5% Shatavarin IV) or placebo for 8 weeks.
For brands and healthcare professionals asking how long does shatavari take to work, the trial data provides a definitive answer — with measurable improvements emerging as early as Week 4. Key clinical outcomes are as follows:
1. Overall MRS Score Changes
Baseline: No significant difference in MRS scores between groups (SheVari4: 14.57 ± 1.32; Placebo: 15.42 ± 1.35; p = 0.655).
Week 4: SheVari4 group MRS score decreased to 8.29 ± 1.29 (43% reduction); Placebo: 15.92 ± 1.32. Difference was highly significant (p < 0.001).
Week 8: SheVari4 group MRS score decreased to 4.26 ± 1.16 (71% reduction, approaching symptom-free level); Placebo: 15.68 ± 1.19. Difference was highly significant (p < 0.001).
Figure 1. Menopausal symptoms were significantly alleviated at Week 4 and Week 8 after administration of SheVari4.
Figure 2. Distribution of total Menopause Rating Scale (MRS) scores in each group and the improving trend of menopausal symptoms in the SheVari4 group.
2. Individual Symptom Improvements (MRS Subscores)
Somatic symptoms:
Hot flashes and sleep disturbances showed the most pronounced improvement. By Week 8, hot flash improvement reached 91.44% and sleep disturbance improvement reached 93.38%.
Psychological symptoms:
Already significantly improved by Week 4. By Week 8, improvement reached 80–90%, with depressive mood improving 84.92% and irritability improving 41.50%.
Urogenital symptoms:
Significant improvement was not observed until Week 8, suggesting a longer intervention period may be required. Vaginal dryness improved 46.08% and sexual dysfunction improved 61.54%.
Heart discomfort, joint and muscle pain showed no significant difference between groups, likely due to mild baseline symptoms (scores approaching 0) with limited room for improvement.
Figure 3. Average percentage reduction in each subscore of the Menopause Rating Scale (MRS) with statistically significant differences
3. Subgroup Analysis (Stratified by Baseline Severity)
Mild (MRS 0–15): Week 8 score decreased by 74.52%
Severe (MRS ≥16): Week 8 score decreased by 72.91%
Conclusion: SheVari4 was effective in both mild and severe symptom groups, with similar improvement magnitude (approximately 70–75%), while placebo was nearly ineffective. This confirms the broad applicability of SheVari4, independent of baseline symptom severity.
Figure 4. MRS scores improved over the treatment duration with SheVari4 regardless of baseline scores
4. Safety Outcomes
Adverse events were mild, transient, and required no intervention. No statistically significant differences were observed between groups.
SheVari4 group: Mild gastrointestinal discomfort (10%), headache (6.7%), nausea (3.3%)
Placebo group: Mild gastrointestinal discomfort (6.7%), headache (10%), nausea (6.7%), dizziness (3.3%)
Blood routine and body weight showed no significant changes after 8 weeks in either group. No serious adverse events occurred.
These findings are further corroborated by a separate multicenter RCT in 70 women, which also demonstrated significant improvement in menopausal quality of life with standardized shatavari root extract [9].
What Is SheVari4™?
SheVari4™ is a patented, standardized shatavari root extract developed by Cepham Inc., a New Jersey-based botanical ingredient company. The “4” in the name refers to its standardization to ≥5% Shatavarin IV — the specific bioactive compound associated with phytoestrogenic and adaptogenic activity.
While shatavari powder benefits for female wellness are well-recognized in traditional use, undifferentiated powders lack the standardization needed for reliable clinical outcomes. Unlike generic shatavari powders or undifferentiated extracts, SheVari4 is:
Standardized to a clinically relevant marker compound (Shatavarin IV ≥5%)
Supported by a published randomized controlled trial (RCT)
Manufactured under strict quality controls
Designed specifically for women experiencing perimenopausal and menopausal symptoms
The result is an ingredient that formulators can trust for both potency and reproducibility — two things that matter enormously when making health claims.
Shatavari Side Effects and Safety: What You Need to Know
Shatavari has a long history of traditional use and is generally regarded as well-tolerated [1, 4]. In the published RCT, adverse events were mild and transient, with no serious safety signals observed in the SheVari4 group. The standardized, low-dose format (100 mg/day) further supports a favorable safety profile.
As with any botanical supplement, women who are pregnant, breastfeeding, or taking medications that interact with estrogen pathways should consult a healthcare provider before use.
Who Should Consider a Standardized Shatavari Supplement?
SheVari4’s combination of clinical backing, clean botanical positioning, and broad symptom coverage makes it a strong fit across a range of product categories and brand strategies. Here’s where it tends to work best:
Women’s menopause and perimenopause formulas The most obvious application. SheVari4’s randomized controlled trial (RCT) was conducted in women aged 40–55 experiencing pre-, peri-, and post-menopausal symptoms. This makes it one of the few standardized shatavari ingredients with clinical data directly relevant to this population. For brands developing menopause-focused products such as capsules, softgels, or powders, this provides a stronger scientific foundation for product positioning and communication.
Hormonal balance and “cycle support” products Shatavari has a wide range of uses for female hormonal health, from PMS relief and endocrine support to cycle regulation. The phytoestrogenic activity of Shatavarin IV extends well beyond menopause, supporting multiple aspects of hormonal balance. For brands formulating products for broader hormonal support or women’s cycle health, SheVari4™ can serve as a versatile adaptogen with hormone-modulating properties.
Stress and sleep supplements with a women’s health angle SheVari4’s cortisol-regulating, adaptogenic mechanism makes it a natural fit for sleep and stress formulas targeted at women in their 40s and 50s — a demographic increasingly aware of the connection between stress hormones and menopause symptoms
Clean label and Ayurveda-positioned lines As consumer demand for traditional, plant-based wellness continues to grow, shatavari’s deep Ayurvedic roots give it strong storytelling appeal [1, 4]. SheVari4 brings that heritage together with modern standardization and published science — a combination that resonates with both clean-label and evidence-based brand identities.
Combination formulas targeting multiple menopause pathways SheVari4 stacks well with other evidence-backed women’s health actives. Its adaptogenic profile complements phytoestrogen-focused ingredients, making it a versatile anchor in multi-ingredient formulations designed to cover a wider symptom spectrum.
Pairing Shatavari with Other Ingredients for Better Results
While SheVari4 offers robust single-ingredient efficacy, advanced formulations are increasingly pairing it with complementary actives that target different biological pathways.
+ S-Equol: A metabolite of the soy isoflavone daidzein, S-equol can be naturally produced by only 20–30% of Western women via gut microbiota — meaning the majority may benefit from direct supplementation [10]. When paired with SheVari4, S-equol extends phytoestrogenic coverage by targeting estrogen receptor beta through a complementary mechanism.
+ Ashwagandha (Withania somnifera): As a second adaptogen with a well-established cortisol-modulating mechanism, ashwagandha forms a dual-adaptogen pairing with SheVari4 that synergistically amplifies stress relief. During perimenopause, declining estrogen and rising cortisol interact to compound fatigue, mood disruption, and sleep difficulties — a two-front challenge where combining these adaptogens addresses HPA axis dysregulation more comprehensively than either herb alone.
+ Vitamin D3 / Calcium: Bone density loss accelerates sharply during the perimenopausal transition as estrogen levels decline. Pairing SheVari4’s phytoestrogenic activity with vitamin D3 and calcium creates a targeted approach to perimenopause skeletal health — addressing both the hormonal and nutritional dimensions of bone protection simultaneously. This stack is particularly relevant for women in the early perimenopausal stage, when bone health interventions deliver the greatest long-term benefit.
+ Probiotics / Prebiotics: Emerging research on the gut–hormone axis highlights the critical role of intestinal microbiota in estrogen metabolism — a regulatory pathway sometimes referred to as the “estrobolome.” Probiotic and prebiotic supplementation supports a healthier gut microbiome composition, potentially enhancing bioavailable estrogen metabolites and improving phytoestrogen conversion. Pairing SheVari4 with gut-supportive ingredients delivers a more integrated approach to hormonal balance by simultaneously targeting the microbiome dimension of estrogen regulation.
For brands looking to build out a full-spectrum menopause formula, understanding how these ingredients interact — and which suppliers offer clinically validated raw materials — is an important part of the development process.
Where to Source a Clinically Validated Shatavari Extract
SheVari4™ is a patented ingredient manufactured by Cepham Inc. For supplement brands, contract manufacturers, and formulators seeking to incorporate this ingredient into their product lines, it is available through authorized distribution partners.
We are proud to serve as an authorized distributor of SheVari4 for the Asia-Pacific market. Whether you’re building a standalone menopause formula or integrating SheVari4 into a broader women’s wellness stack, our team can support you with ingredient sourcing, documentation, and formulation guidance.
For inquiries about SheVari4 availability, minimum order quantities, and pricing, please contact us.
Final Thoughts
The women’s menopause supplement market is growing rapidly — but it’s also crowded with underdosed, unstandardized products that fail to deliver real results. SheVari4 stands out because it combines the credibility of an Ayurvedic tradition with the rigor of modern clinical science: a standardized extract, published RCTs, and a clear mechanism of action.
For supplement brands serious about women’s health, it’s one of the most compelling raw ingredients available today — and the clinical evidence for shatavari benefits for females across pre-, peri-, and post-menopausal stages makes the case stronger than ever.
This article is for informational purposes only and does not constitute medical advice. Please consult a qualified healthcare provider before starting any new supplement or treatment regimen.
References:
[1] Selvaraj K, Sivakumar G, Veeraraghavan VP, et al. Asparagus racemosus - a review. Sys Rev Pharm. 2019, 10:3.
[2] Kohli D, Champawat PS, Mudgal VD. Asparagus (Asparagus racemosus L.) roots: nutritional profile, medicinal profile, preservation, and value addition. J Sci Food Agric. 2023, 103:2239–50. doi: 10.1002/jsfa.12358
[3] Sushma, Yadava LP. Shatavari (Asparagus racemosus Willd): a herbal boon to women reproductive health and an overview of current research. World J Adv Res Rev. 2022, 16:32–8. doi: 10.30574/wjarr.2022.16.2.1028
[4] Bopana N, Saxena S. Asparagus racemosus — ethnopharmacological evaluation and conservation needs. J Ethnopharmacol. 2007, 110:1–15. doi: 10.1016/j.jep.2007.01.001
[5] Arora N, Banerjee AK. Molecular docking analysis of shatavarins with female hormonal receptors. Bioinformation. 2024, 20:775–80. doi: 10.6026/973206300200775
[6] Sharma R, Jaitak V. Asparagus racemosus (Shatavari) targeting estrogen receptor α: an in-vitro and in-silico mechanistic study. Nat Prod Res. 2020, 34:1571–4. doi: 10.1080/14786419.2018.1517123
[7] Santoro N, Randolph JF Jr. Reproductive hormones and the menopause transition. Obstet Gynecol Clin North Am. 2011, 38:455–66.
[8] Shatavarin IV, a Bioactive Constituent of Asparagus racemosus, Exerts Antioxidant and Anti-Inflammatory Effects in LPS-Treated Cultured SH-SY5Y Cells via TrkB-BDNF Axis. J Am Nutr Assoc. 2025. doi: 10.1080/27697061.2025.2607514
[9] Gudise VS, Dasari MP, Kuricheti SSK. Efficacy and safety of shatavari root extract for the management of menopausal symptoms: a double-blind, multicenter, randomized controlled trial. Cureus. 2024;16(4):e57879. doi: 10.7759/cureus.57879
[10] Setchell KDR, Clerici C. Equol: history, chemistry, and formation. J Nutr. 2010;140(7):1355S–62S. doi: 10.3945/jn.109.119768
+1(425)866-9043
sales@bonerge.com